Immune Pharmaceuticals (NASDAQ: IMNP) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Immune Pharmaceuticals to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.

Valuation & Earnings

This table compares Immune Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Immune Pharmaceuticals N/A -$32.66 million -0.20
Immune Pharmaceuticals Competitors $8.17 billion $1.09 billion 127.03

Immune Pharmaceuticals’ peers have higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Immune Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals’ peers have a beta of 34.20, suggesting that their average stock price is 3,320% more volatile than the S&P 500.


This table compares Immune Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Pharmaceuticals N/A -1,443.76% -117.17%
Immune Pharmaceuticals Competitors -2,436.30% -70.63% -7.85%

Analyst Ratings

This is a breakdown of current ratings and price targets for Immune Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immune Pharmaceuticals 0 0 0 0 N/A
Immune Pharmaceuticals Competitors 875 3806 6784 181 2.54

As a group, “Pharmaceuticals” companies have a potential upside of 20.87%. Given Immune Pharmaceuticals’ peers higher possible upside, analysts clearly believe Immune Pharmaceuticals has less favorable growth aspects than its peers.

Institutional and Insider Ownership

1.6% of Immune Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.7% of Immune Pharmaceuticals shares are owned by insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Immune Pharmaceuticals peers beat Immune Pharmaceuticals on 8 of the 9 factors compared.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Receive News & Ratings for Immune Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc and related companies with's FREE daily email newsletter.